Early study shows possibility of combining CPT1A enzyme with Xtandi. In fact, we are already able to block the action of the CPT1A enzyme. The drug ranolazine is a fat oxidation inhibitor that earned FDA approval in 2006 to treat angina.
/www.sciencedaily.com/releases/2017/05/170515125937.htmPost Edited (RobertC) : 5/16/2017 7:13:05 AM (GMT-6)